Canisius-Wilhelmina Ziekenhuis

Nijmegen, Gelderland 6532 SZ

3 studies enrolling now · 13 studies all time

What they study most

Acute Kidney Injury, Cancer of the Prostate, Castration-resistant Prostate Cancer, Chronic Cluster Headache, Cluster Headache, Episodic, Hormone Sensitive Prostate Cancer, Menstrual Migraine, Metastatic Castrate Resistant Prostate Cancer (mCRPC), Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer, Migraine, Prostate Cancer

Studies at this site

• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. — Recruiting now
• A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. — Recruiting now
• A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine — Recruiting now
• A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer — Running, not enrolling
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes — Completed
• A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). — Running, not enrolling
• HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Stopped early
• Eptinezumab in Participants With Episodic Cluster Headache — Completed
• A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH) — Completed
• Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations — Stopped early
• A Study of Lasmiditan (LY573144) Over Four Migraine Attacks — Completed
• A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine — Completed
• A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI — Completed